Associated Papers
Spatial multi-omics unveils the monoclonal origin, neuroendocrine plasticity, and microenvironment niches in combined small cell lung cancer.
Wang Z et al.
Biorxiv : the Preprint Server for Biology, 2026
PRIME: an interpretable artificial intelligence model based on liquid biopsy improves prediction of progression risk in non-small cell lung cancer.
Wang Y et al.
Military Medical Research, 2026
Mutational landscape of lung adenocarcinoma in Czechia.
Ambrozkiewicz F et al.
Cancer Treatment and Research Communications, 2026
Lymphoid enhancer-binding factor 1 (LEF1) immunostaining as a surrogate for β-catenin (CTNNB1) mutations.
Hewer E et al.
Journal of Clinical Pathology, 2025
Multiple primary cancers with prostate malignant tumor as the initial diagnosis: a case report.
Yang K et al.
Discover Oncology, 2025
Personalized and Tumor Informed Circulating Tumor DNA Assay for Molecular Residual Disease Monitoring of Solid Malignancies.
Liu L et al.
Medcomm, 2025
Clinical and genomic features of Lynch syndrome differ by tumor site and disease spectrum.
Li S et al.
Nature Communications, 2025
TTF-1 and p40 co-expression defines a distinct subtype of non-small cell lung cancer with frequent TP53 mutations and FGFR pathway dysregulation.
Braun M et al.
Translational Lung Cancer Research, 2025
Whole-miRNome sequencing: a panel for the targeted sequencing of all human miRNA genes.
Galka-Marciniak P et al.
Nucleic Acids Research, 2025
Clinical utility of liquid biopsy next-generation sequencing for advanced non-small cell lung cancer in the Netherlands.
de Bitter TJJ et al.
Scientific Reports, 2025
A DNA alteration and methylation co-detection method for clinical purpose.
Yu J et al.
Embo Molecular Medicine, 2025
Comprehensive Evaluation of a 1021-Gene Panel in FFPE and Liquid Biopsy for Analytical and Clinical Use.
Meintani A et al.
International Journal of Molecular Sciences, 2025
Comprehensive molecular profiling of advanced NSCLC using NGS: Prevalence of druggable mutations and clinical trial opportunities in the ATLAS study.
Serna-Blasco R et al.
Lung Cancer (amsterdam, Netherlands), 2025
Detection of actionable mutations in circulating tumor DNA for non-small cell lung cancer patients.
van der Leest P et al.
Communications Medicine, 2025
Clinical Validation of a Targeted RNA-Sequencing Assay for Driver Gene Alteration Detection in Non-Small Cell Lung Cancer.
Li J et al.
Molecular Diagnosis & Therapy, 2025
Prevalence of EGFR gene mutations in patients with early-stage resectable non-small cell lung cancer in Spain: the ORIGEN study.
Varela M et al.
Translational Lung Cancer Research, 2025
Establishment and Characterization of a Brain Parenchymal Metastatic Cell Line AlmoR1 Derived From an NSCLC Patient With EGFR-TKI Resistance.
Wu J et al.
Cancer Medicine, 2025
Multi-gene panel sequencing reveals the relationship between driver gene mutation and clinical characteristics in lung adenocarcinoma.
Li J et al.
Discover Oncology, 2025
Resectable Non-Small Cell Lung Cancer Heterogeneity and Recurrence Assessed by Tissue Next-Generation Sequencing Genotyping and Circulating Tumor Cell EZH2 Characterization.
Garcia-Diaz A et al.
Archivos De Bronconeumologia, 2025
Multicenter In-House Evaluation of an Amplicon-Based Next-Generation Sequencing Panel for Comprehensive Molecular Profiling.
Jantus-Lewintre E et al.
Molecular Diagnosis & Therapy, 2025
Diverse clinical outcomes for the EGFR‑mutated and ALK‑rearranged advanced non‑squamous non‑small cell lung cancer.
Lin CW et al.
Oncology Letters, 2025
Comprehensive characterization of early-onset lung cancer, in Chinese young adults.
Tian Y et al.
Nature Communications, 2025
Absolute Quantification of Nucleotide Variants in Cell-Free DNA via Quantitative NGS: Clinical Application in Non-Small Cell Lung Cancer Patients.
Herbreteau G et al.
Cancers, 2025
Distribution of EGFR and KRAS Mutations in Patients with Surgically Resected Non-Small Cell Lung Cancer from Southern Italy: Real-Life Data from a Single Institution and Literature Review.
Piazzolla M et al.
Cancers, 2025
Possible new mechanisms of primary drug resistance in NSCLC with EGFR mutation treated with Osimertinib.
Shao L et al.
Iubmb Life, 2025
Detection of Overlooked Rare EGFR Mutations in Non-small Cell Lung Cancer Using Multigene Testing.
Shiraishi N et al.
Thoracic Cancer, 2025
Utilizing TP53 hotspot mutations as effective predictors of gemcitabine treatment outcome in non-small-cell lung cancer.
Tseng YH et al.
Cell Death Discovery, 2025
Importance of EQA/PT for the detection of genetic variants in comprehensive cancer genome testing.
Matsushita K et al.
Scientific Reports, 2025
KEAP1-NRF2 Pathway as a Novel Therapeutic Target for EGFR-Mutant Non-small Cell Lung Cancer.
Choi JS et al.
Tuberculosis and Respiratory Diseases, 2025
Importance of driver gene mutation assessment and targeted therapy for patients with early‑stage non‑small cell lung cancer and non‑R0 resection.
Shen PY et al.
Oncology Letters, 2025
Prolonged response to osimertinib in three patients with refractory metastatic pancreatic adenocarcinomas with EGFR exon 19 deletion: a case report and literature review.
Vigié T et al.
Therapeutic Advances in Medical Oncology, 2025
Metastatic INI-1-deficient undifferentiated lung cancer with EGFR 19del mutation identified in pleural effusion: a case report and review of the literature.
Guo Z et al.
Frontiers in Oncology, 2025
Genetic alterations affect immune contexture of non-small cell lung cancer: Ukrainian study.
Kozakov D et al.
Frontiers in Medicine, 2025
Comparison of targeted next generation sequencing assays in non-small cell lung cancer patients.
Drejeriene I et al.
Discover Oncology, 2024
The relevance of the reference range for EGFR testing in non-small cell lung cancer patients.
Pisapia P et al.
Lung Cancer (amsterdam, Netherlands), 2024
Intratumoral heterogeneity of oncogenic drivers in mixed histology lung adenocarcinomas: How tissue selection impacts molecular testing?
Krishnamurthy K et al.
Pathology, Research and Practice, 2024
Super multiple primary lung cancers harbor high-frequency BRAF and low-frequency EGFR mutations in the MAPK pathway.
Li H et al.
Npj Precision Oncology, 2024
Successful rapid improvement of acute respiratory distress syndrome induced by EGFR-mutated non-small cell lung cancer with almonertinib: a case report.
Sun C et al.
Bmc Pulmonary Medicine, 2024
Highly Sensitive 3D-Nanoplasmonic-Based Epidermal Growth Factor Receptor Mutation Multiplex Assay Chip for Liquid Biopsy.
Lee JY et al.
Small Science, 2024
The Advantage of Targeted Next-Generation Sequencing over qPCR in Testing for Druggable EGFR Variants in Non-Small-Cell Lung Cancer.
Szpechcinski A et al.
International Journal of Molecular Sciences, 2024
A case of Ph+ acute lymphoblastic leukemia and EGFR mutant lung adenocarcinoma synchronous overlap: may one TKI drug solve two diseases?
Zhang Q et al.
Bmc Medical Genomics, 2024
High-efficiency EGFR genotyping using cell-free DNA in bronchial washing fluid.
Murata Y et al.
Japanese Journal of Clinical Oncology, 2024
Unravelling the role of PLK1 in tumorigenesis by revealing the mutational landscape of colorectal and lung cancer with PLK1 mutations.
Wang S et al.
Journal of Cellular and Molecular Medicine, 2024
Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib.
de Jager VD et al.
Npj Precision Oncology, 2024
External Quality Assessment on Molecular Tumor Profiling with Circulating Tumor DNA-Based Methodologies Routinely Used in Clinical Pathology within the COIN Consortium.
van der Leest P et al.
Clinical Chemistry, 2024
Clinical relevance of somatic mutations in Chinese lung adenocarcinoma and their prognostic implications for survival.
Li T et al.
Cancer Medicine, 2024